New patent expiration for Evoke Pharma drug GIMOTI
Annual Drug Patent Expirations for GIMOTI Gimoti is a drug marketed by Evoke Pharma Inc and is included in one […]
New patent expiration for Evoke Pharma drug GIMOTI Read Post »
Patent Expiration
New patent expiration for R-pharm Us drug IXEMPRA KIT
Annual Drug Patent Expirations for IXEMPRA+KIT Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in
New patent expiration for R-pharm Us drug IXEMPRA KIT Read Post »
Drug Patent Expirations for the Week of March 21, 2021
XOPENEX (levalbuterol hydrochloride) Akorn Patent: 6,451,289 Expiration: Mar 21, 2021 See More … For more information on how DrugPatentWatch can
Drug Patent Expirations for the Week of March 21, 2021 Read Post »
New patent expiration for AKORN drug XOPENEX
Annual Drug Patent Expirations for XOPENEX Xopenex is a drug marketed by Akorn and Sunovion and is included in two
New patent expiration for Recordati Rare drug NEOPROFEN
Annual Drug Patent Expirations for NEOPROFEN Neoprofen is a drug marketed by Recordati Rare and is included in one NDA.
New patent expiration for Recordati Rare drug NEOPROFEN Read Post »
New patent expiration for Takeda Pharms drug ACTOPLUS MET XR
Annual Drug Patent Expirations for ACTOPLUS+MET+XR Actoplus Met Xr is a drug marketed by Takeda Pharms Usa and is included
New patent expiration for Takeda Pharms drug ACTOPLUS MET XR Read Post »
New patent expiration for Andrx Labs drug FORTAMET
Annual Drug Patent Expirations for FORTAMET Fortamet is a drug marketed by Andrx Labs Llc and is included in one
New patent expiration for Andrx Labs drug FORTAMET Read Post »
Drug Patent Expirations for the Week of March 14, 2021
TWIRLA (ethinyl estradiol; levonorgestrel) Agile Patent: 7,045,145 Expiration: Mar 14, 2021 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of March 14, 2021 Read Post »
New patent expiration for AGILE drug TWIRLA
Annual Drug Patent Expirations for TWIRLA Twirla is a drug marketed by Agile and is included in one NDA. There
